Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint

FDA questions whether imaging improvements in patients with glioblastoma metaforme are sufficient to denote clinical change.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet